Quote | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
Last: | $0.93 |
---|---|
Change Percent: | -2.11% |
Open: | $0.93 |
Close: | $0.93 |
High: | $0.96 |
Low: | $0.89 |
Volume: | 50,284 |
Last Trade Date Time: | 05/06/2022 04:56:05 pm |
News | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
Message Board Posts | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Satellos Bioscience Inc. Company Name:
MSCL:CC Stock Symbol:
TSXVC Market:
Satellos Bioscience Inc. Website:
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...